Table 2.
Characteristics of all patients according to receipt of immunotherapy in each cohort.
| Variable | SEER Cohort | Single-Center Cohort | ||||
|---|---|---|---|---|---|---|
| No immunotherapyN=261 (%) | ImmunotherapyN=222 (%) | P | No immunotherapyN=163 (%) | ImmunotherapyN=181 (%) | P | |
| Age | ||||||
| <65 | 146 (55.9%) | 116 (52.3%) | 0.418 | 56 (34.4%) | 64 (35.4%) | 0.845 |
| ‗65 | 115 (44.1%) | 106 (47.7%) | 107 (65.6%) | 117 (64.6%) | ||
| Sex | ||||||
| Male | 152 (58.2%) | 123 (55.4%) | 0.531 | 98 (60.1%) | 100 (55.2%) | 0.361 |
| Female | 109 (41.8%) | 99 (44.6%) | 65 (39.9%) | 81 (44.8%) | ||
| Origin | ||||||
| Left | 111 (42.5%) | 94 (42.3%) | 0.967 | 68 (41.7%) | 68 (37.6%) | 0.432 |
| Right | 150 (57.5%) | 128 (57.7%) | 95 (58.3%) | 113 (62.4%) | ||
| Histology | ||||||
| Squamous cell carcinoma | 89 (34.1%) | 57 (25.7%) | 0.056 | 60 (36.8%) | 59 (32.6%) | 0.412 |
| Others | 172 (65.9%) | 165 (74.3%) | 103 (63.2%) | 122 (67.4%) | ||
| T stage | ||||||
| T1 | 69 (26.4%) | 50 (22.5%) | 0.086 | 28 (17.2%) | 16 (8.8%) | 0.110 |
| T2 | 45 (17.2%) | 40 (18.0%) | 52 (31.9%) | 61 (33.7%) | ||
| T3 | 95 (36.4%) | 73 (32.9%) | 65 (39.9%) | 78 (43.1%) | ||
| T4 | 49 (18.8%) | 59 (26.6%) | 14 (8.6%) | 24 (13.3%) | ||
| Unknown | 3 (1.1%) | 0 (0.0%) | 4 (2.5%) | 2 (1.1%) | ||
| N stage | ||||||
| N0 | 114 (43.7%) | 86 (38.7%) | 0.483 | 82 (50.3%) | 79 (43.6%) | 0.666 |
| N1 | 34 (13.0%) | 30 (13.5%) | 18 (11.0%) | 23 (12.7%) | ||
| N2 | 81 (31.0%) | 66 (29.7%) | 43 (26.4%) | 48 (26.5%) | ||
| N3 | 25 (9.6%) | 31 (14.0%) | 18 (11.0%) | 28 (15.5%) | ||
| Unknown | 7 (2.7%) | 9 (4.1%) | 2 (1.2%) | 3 (1.7%) | ||
| Radiation status | ||||||
| No | 117 (44.8%) | 100 (45.0%) | 0.962 | 69 (42.3%) | 90 (49.7%) | 0.206 |
| Yes | 144 (55.2%) | 122 (55.0%) | 94 (57.7%) | 91 (50.3%) | ||
| Bone metastasis | ||||||
| No | 182 (69.7%) | 141 (63.5%) | 0.148 | 108 (66.3%) | 110 (60.8%) | 0.292 |
| Yes | 79 (30.3%) | 81 (36.5%) | 55 (33.7%) | 71 (39.2%) | ||
| Brain metastasis | ||||||
| No | 153 (58.6%) | 130 (58.6%) | 0.989 | 109 (66.9%) | 107 (59.1%) | 0.169 |
| Yes | 108 (41.4%) | 92 (41.4%) | 54 (33.1%) | 74 (40.9%) | ||
| Liver metastasis | ||||||
| No | 223 (85.4%) | 185 (83.3%) | 0.524 | 34 (20.9%) | 42 (23.2%) | 0.601 |
| Yes | 38 (14.6%) | 37 (16.7%) | 129 (79.1%) | 139 (76.8%) | ||
| Metastasis site | ||||||
| BOM | 55 (21.1%) | 55 (21.6%) | 0.225 | 40 (24.5%) | 39 (21.5%) | 0.563 |
| BRM | 92 (35.2%) | 68 (30.6%) | 41 (25.2%) | 41 (22.7%) | ||
| LIM | 27 (10.3%) | 18 (8.1%) | 13 (8.0%) | 17 (9.4%) | ||
| MOM | 24 (9.6%) | 35 (15.8%) | 26 (16.0%) | 41 (22.7%) | ||
| OTM | 63 (23.8%) | 53 (23.9%) | 43 (26.4%) | 43 (23.8%) | ||
BOM, bone metastases only; BRM, brain metastases only; LIM, liver metastases only; MOM, multiple organ metastases; OTM, other metastases.
*p value is significant